{
    "clinical_study": {
        "@rank": "33727", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor\n      cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with or\n      without radiation therapy in treating patients who have esophageal cancer."
        }, 
        "brief_title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer", 
        "completion_date": {
            "#text": "April 2009", 
            "@type": "Actual"
        }, 
        "condition": "Esophageal Cancer", 
        "condition_browse": {
            "mesh_term": "Esophageal Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the median and two-year disease-free and overall survival of patients with\n           resectable esophageal cancer treated with neoadjuvant paclitaxel, cisplatin, and\n           fluorouracil with concurrent radiotherapy.\n\n        -  Determine the complete and partial responses in patients treated with this regimen.\n\n        -  Assess the toxicity of this regimen in these patients.\n\n        -  Determine the optimal dose of paclitaxel when administered in this regimen in these\n           patients.\n\n        -  Determine the effect of tumor tubulin isoform expression on chemosensitivity and\n           overall survival of patients treated with this regimen.\n\n      OUTLINE: Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1.\n      Treatment repeats every 3 weeks for 2 courses.\n\n      Beginning 3 weeks after completion of initial chemotherapy, patients receive concurrent\n      chemoradiotherapy comprising paclitaxel IV over 1 hour and cisplatin IV over 1 hour on days\n      1, 8, 15, 22, and 29; fluorouracil IV continuously for 5 weeks; and radiotherapy daily 5\n      days a week for 5 weeks.\n\n      At 4-8 weeks after completion of chemoradiotherapy, patients may undergo surgical resection.\n      Patients with local progressive disease after 2 courses of initial chemotherapy undergo\n      surgical resection instead of receiving concurrent chemoradiotherapy.\n\n      Patients are followed within 6 weeks, every 3 months for 3 years, and then annually for 2\n      years.\n\n      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed adenocarcinoma, squamous cell, adenosquamous, or\n             undifferentiated carcinoma of the esophagus or gastroesophageal junction\n\n               -  Potentially resectable disease\n\n          -  No malignant celiac node involvement\n\n          -  No cervical esophageal carcinoma\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,800/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n\n          -  AST no greater than 3 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Other:\n\n          -  No other malignancy within the past 3 years except nonmelanoma skin cancer or\n             carcinoma in situ of the cervix\n\n          -  No significant medical or psychiatric illness that would preclude study\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception during and for at least 3 months\n             after study\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  No prior chemotherapy for esophageal cancer\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  No prior thoracic radiotherapy\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n          -  No prior surgical resection of esophageal tumor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 11, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00021320", 
            "org_study_id": "CDR0000068769", 
            "secondary_id": [
                "P30CA006927", 
                "FCCC-00003", 
                "NCI-G01-1982"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "fluorouracil", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "neoadjuvant therapy", 
                "intervention_type": "Procedure"
            }, 
            {
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Fluorouracil", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage 0 esophageal cancer", 
            "stage I esophageal cancer", 
            "stage II esophageal cancer", 
            "stage III esophageal cancer", 
            "squamous cell carcinoma of the esophagus", 
            "adenocarcinoma of the esophagus"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/FCCC-00003"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19111-2497"
                }, 
                "name": "Fox Chase Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer", 
        "overall_official": {
            "affiliation": "Fox Chase Cancer Center", 
            "last_name": "Jonathan Cheng, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00021320"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fox Chase Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fox Chase Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }, 
    "geocoordinates": {
        "Fox Chase Cancer Center": "39.952 -75.164"
    }
}